Abstract |
In this issue of Cancer Cell, Maes and colleagues report in vitro and in vivo findings with ORY-1001-an oral, highly potent and selective covalent small-molecule inhibitor of lysine-specific demethylase 1 (LSD1)-in development for acute myeloid leukemia (AML), as well as correlative data from two AML patients receiving ORY-1001.
|
Authors | Prithviraj Bose, Marina Y Konopleva |
Journal | Cancer cell
(Cancer Cell)
Vol. 33
Issue 3
Pg. 342-343
(03 12 2018)
ISSN: 1878-3686 [Electronic] United States |
PMID | 29533778
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Comment)
|
Copyright | Copyright © 2018 Elsevier Inc. All rights reserved. |
Chemical References |
|
Topics |
- Cell Differentiation
- Histone Demethylases
- Humans
- Leukemia, Myeloid, Acute
|